Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study
Frank Vinluan , 2025-07-15 17:52:00 A Hengrui Pharma obesity drug designed to hit two targets led to an average of nearly 18% weight loss in a pivotal study, paving the way for a regulatory submission in China, where the trial was conducted and the company is based. These results are also encouraging for biotech startup…